One year follow-up of patients with familial hypercholesterolemia: Preliminary data from the HELLAS-FH registry

Abstract

Background and Aims : To report follow-up findings in patients from the HELLAS-FH registry.Methods: We evaluated 139 adult patients with a clinical diagnosis of FH with a median follow-up of 12 months. Patient demographics, lipid profile, treatment and atherosclerotic cardiovascular disease (ASCVD) profile were recorded.Results: Patients were 53.2% male and aged 48.8±13.8 years. A proportion of 67.6% were receiving hypolipidemic treatment at enrollment and lipid profile was: total cholesterol (TCHOL) 215±60 mg/dL, low-density lipoprotein cholesterol (LDL-C) 141±55 mg/dL, high-density lipoprotein cholesterol (HDL-C) 49±13 mg/dL and triglycerides (TGs) 112 (77-156) mg/dL. Only 5.2% of on-treatment patients were on LDL-C target. After a median follow-up of 12 months (IQR 4-31 months), all patients were receiving hypolipidemic treatment. Specifically, 33.3% of patients started statin therapy, 22.7% had their statin therapy uptitrated, in 35.5% ezetimibe was added and in 14.2% a PCSK9i was prescribed. Follow-up lipid profile was: TCHOL 178±51 mg/dL, LDL-C 107±47 mg/dL, HDL-C 53±16 mg/dL and TGs 100 (70-136) mg/dL. At follow-up, 4.2% of patients were on target for LDL-C goal. Regarding ASCVD, 1 non-fatal myocardial infarction and 3 new diagnoses of peripheral arterial disease were recorded.Conclusions: After a median follow-up of 12 months, intensification of hypolipidemic therapy accompanied by an improvement of lipid profile was observed. Despite that, achievement of LDL-C target remained poor. A new ASCVD event was recorded in 2.8% of patients. Background and Aims : To report follow-up findings in patients from the HELLAS-FH registry. Methods: We evaluated 139 adult patients with a clinical diagnosis of FH with a median follow-up of 12 months. Patient demographics, lipid profile, treatment and atherosclerotic cardiovascular disease (ASCVD) profile were recorded. Results: Patients were 53.2% male and aged 48.8±13.8 years. A proportion of 67.6% were receiving hypolipidemic treatment at enrollment and lipid profile was: total cholesterol (TCHOL) 215±60 mg/dL, low-density lipoprotein cholesterol (LDL-C) 141±55 mg/dL, high-density lipoprotein cholesterol (HDL-C) 49±13 mg/dL and triglycerides (TGs) 112 (77-156) mg/dL. Only 5.2% of on-treatment patients were on LDL-C target. After a median follow-up of 12 months (IQR 4-31 months), all patients were receiving hypolipidemic treatment. Specifically, 33.3% of patients started statin therapy, 22.7% had their statin therapy uptitrated, in 35.5% ezetimibe was added and in 14.2% a PCSK9i was prescribed. Follow-up lipid profile was: TCHOL 178±51 mg/dL, LDL-C 107±47 mg/dL, HDL-C 53±16 mg/dL and TGs 100 (70-136) mg/dL. At follow-up, 4.2% of patients were on target for LDL-C goal. Regarding ASCVD, 1 non-fatal myocardial infarction and 3 new diagnoses of peripheral arterial disease were recorded. Conclusions: After a median follow-up of 12 months, intensification of hypolipidemic therapy accompanied by an improvement of lipid profile was observed. Despite that, achievement of LDL-C target remained poor. A new ASCVD event was recorded in 2.8% of patients.